Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to

    • Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities

      Net Sales are expected to increase by 1.8 percent Y-o-Y (up 2.3 percent Q-o-Q) to Rs 6,848.5 crore, according to ICICI Securities.

    • Cipla set to launch key drugs Abraxane and Advair in FY26

      Cipla's oncology drug Abraxane will be launched from its Goa facility while respiratory drug Advair will be rolled out from the New Jersey plant.

    • Multiple near-term challenges may hijack Cipla's growth trajectory

      Cipla projects a mid-FY26 launch for Advair, while the release of Abraxane is contingent on regulatory clearance of the company's Goa facility. Respiratory drug Albuterol faces intensifying competition, while similar concerns loom over the blockbuster cancer drug Revlimid, whose patent is set to expire in 2026.

    • Cipla's strong US pipeline, steady Q4 earnings and hopes of easing regulatory snags drive bullishness

      Cipla plans to launch 12 assets in peptides and complex generics space and 5 in the respiratory segment over FY25-27, which brokerages believe will secure its growth path for the next 3-4 years.

    • Cipla Q4 results preview: Revenue boost likely from strong US sales, net profit to jump from low base

      Cipla's US sales likely to surge in Q4, driven by the contribution from Revlimid, along with a stable market share in Albuterol (respiratory drug) and an expansion in Lanreotide (hormonal drug) and Brovana (inhalation drug)

    • Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities

      Net Sales are expected to decrease by 4.7 percent Y-o-Y (up 9.6 percent Q-o-Q) to Rs 6,290.9 crore, according to ICICI Securities.

    • Cipla Q1 PAT seen up 15.6% YoY to Rs 793.7 cr: Nirmal Bang

      Net Sales are expected to increase by 14.8 percent Y-o-Y (up 7.5 percent Q-o-Q) to Rs 6.171.7 crore, according to Nirmal Bang.

    • Cipla Q4 preview: Robust domestic traction, gRevlimid sales likely to give earnings a big boost

    • Cipla Q4 PAT seen up 58% YoY to Rs 6,485 cr: Nirmal Bang

    • Cipla Q3 preview | Consolidated net profit likely to rise 22% YoY

    • Cipla Q3 PAT seen up 33.1% YoY to Rs 9,699 cr: Nirmal Bang

    • Cipla Q2 preview | Consolidated net profit likely to rise 9% YoY

    • Cipla Q1 Preview | Profit may decline 10% YoY on flat revenue

    • Cipla Q1 PAT may dip 23.2% YoY to Rs 645 cr: Prabhudas Lilladher

    • Cipla Results Preview | Consolidated net profit may rise 47% on India ops

    • Cipla Q4 PAT seen up 27.6% YoY to Rs 527.6 cr: Prabhudas Lilladher

    • Cipla Q3 PAT may dip 6.4% YoY to Rs 700.3 cr: Prabhudas Lilladher

    • Cipla Q2 PAT seen up 20.3% YoY to Rs 793.4 cr: Prabhudas Lilladher

    • Cipla Q1 PAT seen up 10.9% YoY to Rs 640.7 cr: KRChoksey

    • Cipla Q1 PAT may dip 7.5% YoY to Rs 534.3 cr: ICICI Direct

    • Cipla Q4 PAT seen up 147.8% YoY to Rs. 609 cr: Sharekhan

    • Cipla Q3 PAT seen up 74.3% YoY to Rs. 612 cr: Yash Securities

    • Cipla Q3 PAT seen up 77.2% YoY to Rs. 351 cr: Prabhudas Lilladher

    • Cipla Q3 PAT seen up 73.2% YoY to Rs. 608.1 cr: ICICI Direct

    • Cipla Q4 profit, revenue could decline due to high-base effect

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347